{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T11:35:40Z","timestamp":1794656140549,"version":"4.9.1"},"reference-count":115,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,2]],"date-time":"2022-10-02T00:00:00Z","timestamp":1664668800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.biopha.2022.113797","type":"journal-article","created":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T11:50:55Z","timestamp":1665229855000},"page":"113797","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"special_numbering":"C","title":["Natural products targeting the ATR-CHK1 signaling pathway in cancer therapy"],"prefix":"10.1016","volume":"155","author":[{"given":"Salman","family":"Ahmed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waqas","family":"Alam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Aschner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalaf F.","family":"Alsharif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashraf","family":"Albrakati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciano","family":"Saso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haroon","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.biopha.2022.113797_bib1","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S1470-2045(12)70211-5","article-title":"Global cancer transitions according to the Human Development Index (2008\u20132030): a population-based study","volume":"13","author":"Bray","year":"2012","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.biopha.2022.113797_bib2","series-title":"Anti-Cancer Drug Discovery and Development in Brazil: Targeted Plant Collection as A Rational Strategy to Acquire Candidate Anti-cancer Compounds","first-page":"185","author":"Mans","year":"2000"},{"issue":"5","key":"10.1016\/j.biopha.2022.113797_bib3","first-page":"1065","article-title":"Anti-prostate cancer activity of a \u03b2-carboline alkaloid enriched extract from Rauwolfia vomitoria","volume":"29","author":"Bemis","year":"2006","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.biopha.2022.113797_bib4","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3390\/ijms21165622","article-title":"Anticancer potential of furanocoumarins: mechanistic and therapeutic aspects","volume":"21","author":"Ahmed","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2022.113797_bib5","first-page":"10","article-title":"Phytochemicals in cancer treatment: from preclinical studies to clinical practice","volume":"2020","author":"Choudhari","year":"1614","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.biopha.2022.113797_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2019.152883","article-title":"Apoptosis induced by luteolin in breast cancer: mechanistic and therapeutic perspectives","volume":"59","author":"Ahmed","year":"2019","journal-title":"Phytomedicine"},{"issue":"2","key":"10.1016\/j.biopha.2022.113797_bib7","first-page":"1","article-title":"A review on the alkaloids an important therapeutic compound from plants","volume":"3","author":"Roy","year":"2017","journal-title":"IJPB"},{"key":"10.1016\/j.biopha.2022.113797_bib8","unstructured":"Barffour, I.K., Anti-hepatocellular carcinoma effect of an alkaloidal extract derived from zanthoxylum zanthoxyloides. 2019, University of Cape Coast."},{"issue":"8","key":"10.1016\/j.biopha.2022.113797_bib9","first-page":"175","article-title":"Phytochemicals and antimicrobial properties of the root and leaf extract of Carica papaya","volume":"5","author":"Chinonye","year":"2016","journal-title":"Int. J. Innov. Res. Dev."},{"issue":"1","key":"10.1016\/j.biopha.2022.113797_bib10","first-page":"424","article-title":"The surprising health benefits of papaya seeds: a review","volume":"6","author":"Kumar","year":"2017","journal-title":"J. Pharmacogn. Phytochem."},{"issue":"2","key":"10.1016\/j.biopha.2022.113797_bib11","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1053\/j.gastro.2009.10.031","article-title":"Des-\u03b3-carboxy prothrombin and \u03b1-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma","volume":"138","author":"Lok","year":"2010","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.biopha.2022.113797_bib12","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41392-020-0150-x","article-title":"DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer","volume":"5","author":"Huang","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"issue":"7","key":"10.1016\/j.biopha.2022.113797_bib13","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.3390\/cells9071665","article-title":"DNA damage: from threat to treatment","volume":"9","author":"Carusillo","year":"2020","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.biopha.2022.113797_bib14","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1039\/C6MD00439C","article-title":"ATM, ATR, CHK1, CHK2 and WEE1 inhibitors in cancer and cancer stem cells","volume":"8","author":"Ronco","year":"2016","journal-title":"MedChemComm"},{"issue":"5","key":"10.1016\/j.biopha.2022.113797_bib15","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3390\/cancers9050041","article-title":"Targeting the ATR-CHK1 axis in cancer therapy","volume":"9","author":"Rundle","year":"2017","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.biopha.2022.113797_bib16","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.tibs.2020.11.002","article-title":"The hammer and the dance of cell cycle control","volume":"46","author":"Panagopoulos","year":"2021","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.biopha.2022.113797_bib17","article-title":"Cell cycle control in cancer","author":"Matthews","year":"2021","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.biopha.2022.113797_bib18","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.pharmthera.2014.12.001","article-title":"ATM and ATR as therapeutic targets in cancer","volume":"149","author":"Weber","year":"2015","journal-title":"Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.biopha.2022.113797_bib19","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.3390\/biom5031912","article-title":"Targeting the checkpoint to kill cancer cells","volume":"5","author":"Benada","year":"2015","journal-title":"Biomolecules"},{"key":"10.1016\/j.biopha.2022.113797_bib20","series-title":"Advances in Cancer Research","first-page":"73","article-title":"Chapter 3 - The ATM\u2013Chk2 and ATR\u2013Chk1 pathways in DNA damage signaling and cancer","author":"Smith","year":"2010"},{"key":"10.1016\/j.biopha.2022.113797_bib21","doi-asserted-by":"crossref","DOI":"10.1017\/erm.2020.3","article-title":"DNA damage checkpoint kinases in cancer","volume":"22","author":"Smith","year":"2020","journal-title":"Expert Rev. Mol. Med."},{"issue":"3","key":"10.1016\/j.biopha.2022.113797_bib22","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.radonc.2017.09.043","article-title":"ATR\/CHK1 inhibitors and cancer therapy","volume":"126","author":"Qiu","year":"2018","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.biopha.2022.113797_bib23","first-page":"50","article-title":"Functions, regulation, and therapeutic implications of the ATR checkpoint pathway","author":"Yazinski","year":"2016","journal-title":"Annu. Rev. Genet."},{"issue":"21","key":"10.1016\/j.biopha.2022.113797_bib24","doi-asserted-by":"crossref","first-page":"4780","DOI":"10.1158\/1078-0432.CCR-15-0479","article-title":"Molecular pathways: targeting ATR in cancer therapy","volume":"21","author":"Karnitz","year":"2015","journal-title":"Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.biopha.2022.113797_bib25","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3390\/cancers13040795","article-title":"Clinical candidates targeting the ATR\u2013CHK1\u2013WEE1 axis in cancer","volume":"13","author":"Gorecki","year":"2021","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.biopha.2022.113797_bib26","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/nrm.2017.67","article-title":"The essential kinase ATR: ensuring faithful duplication of a challenging genome","volume":"18","author":"Saldivar","year":"2017","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"5","key":"10.1016\/j.biopha.2022.113797_bib27","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/ijc.28226","article-title":"Roles of Chk1 in cell biology and cancer therapy","volume":"134","author":"Zhang","year":"2014","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.biopha.2022.113797_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2019.107450","article-title":"Targeting ATR as cancer therapy: a new era for synthetic lethality and synergistic combinations?","volume":"207","author":"Bradbury","year":"2020","journal-title":"Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.biopha.2022.113797_bib29","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/JLB.2MA0321-064R","article-title":"ATR kinase activity promotes antibody class switch recombination in B cells through cell cycle regulation without suppressing DSB resection and microhomology usage","volume":"110","author":"Sun","year":"2021","journal-title":"J. Leukoc. Biol."},{"issue":"12","key":"10.1016\/j.biopha.2022.113797_bib30","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1101\/gad.14.12.1439","article-title":"Aberrant cell cycle checkpoint function and early embryonic death in Chk1\u2212\/\u2212 mice","volume":"14","author":"Takai","year":"2000","journal-title":"Genes Dev."},{"issue":"4","key":"10.1016\/j.biopha.2022.113797_bib31","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1101\/gad.14.4.397","article-title":"ATR disruption leads to chromosomal fragmentation and early embryonic lethality","volume":"14","author":"Brown","year":"2000","journal-title":"Genes Dev."},{"issue":"1","key":"10.1016\/j.biopha.2022.113797_bib32","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1093\/emboj\/17.1.159","article-title":"Overexpression of a kinase-inactive ATR protein causes sensitivity to DNA-damaging agents and defects in cell cycle checkpoints. The","volume":"17","author":"Cliby","year":"1998","journal-title":"EMBO J."},{"issue":"1","key":"10.1016\/j.biopha.2022.113797_bib33","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/ncb2897","article-title":"Causes and consequences of replication stress","volume":"16","author":"Zeman","year":"2014","journal-title":"Nat. Cell Biol."},{"issue":"8","key":"10.1016\/j.biopha.2022.113797_bib34","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1101\/gad.1522607","article-title":"The structural determinants of checkpoint activation","volume":"21","author":"MacDougall","year":"2007","journal-title":"Genes Dev."},{"issue":"9","key":"10.1016\/j.biopha.2022.113797_bib35","doi-asserted-by":"crossref","first-page":"a012716","DOI":"10.1101\/cshperspect.a012716","article-title":"DNA damage sensing by the ATM and ATR kinases","volume":"5","author":"Mar\u00e9chal","year":"2013","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"5547","key":"10.1016\/j.biopha.2022.113797_bib36","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1126\/science.1065521","article-title":"ATR and ATRIP: partners in checkpoint signaling","volume":"294","author":"Cortez","year":"2001","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.biopha.2022.113797_bib37","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.1128\/MCB.02238-06","article-title":"Function of a conserved checkpoint recruitment domain in ATRIP proteins","volume":"27","author":"Ball","year":"2007","journal-title":"Mol. Cell. Biol."},{"issue":"11","key":"10.1016\/j.biopha.2022.113797_bib38","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1101\/gad.1666208","article-title":"TopBP1 activates ATR through ATRIP and a PIKK regulatory domain","volume":"22","author":"Mordes","year":"2008","journal-title":"Genes Dev."},{"issue":"11","key":"10.1016\/j.biopha.2022.113797_bib39","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.dnarep.2005.04.001","article-title":"Identification and functional analysis of TopBP1 and its homologs","volume":"4","author":"Garcia","year":"2005","journal-title":"DNA Repair"},{"key":"10.1016\/j.biopha.2022.113797_bib40","unstructured":"Hussain, R.N., Radiation Biology of Uveal Melanoma. 2020: The University of Liverpool (United Kingdom)."},{"issue":"3","key":"10.1016\/j.biopha.2022.113797_bib41","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1242\/jcs.035105","article-title":"ATR signaling at a glance","volume":"122","author":"Shiotani","year":"2009","journal-title":"J. Cell Sci."},{"issue":"5247","key":"10.1016\/j.biopha.2022.113797_bib42","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1126\/science.271.5247.353","article-title":"rad-dependent response of the chk1-encoded protein kinase at the DNA damage checkpoint","volume":"271","author":"Walworth","year":"1996","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.biopha.2022.113797_bib43","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1101\/gad.14.12.1448","article-title":"Chk1 is an essential kinase that is regulated by Atr and required for the G2\/M DNA damage checkpoint","volume":"14","author":"Liu","year":"2000","journal-title":"Genes Dev."},{"issue":"16","key":"10.1016\/j.biopha.2022.113797_bib44","doi-asserted-by":"crossref","first-page":"6056","DOI":"10.1128\/MCB.00492-06","article-title":"Claspin operates downstream of TopBP1 to direct ATR signaling towards Chk1 activation","volume":"26","author":"Liu","year":"2006","journal-title":"Mol. Cell. Biol."},{"issue":"4","key":"10.1016\/j.biopha.2022.113797_bib45","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S1097-2765(05)00092-4","article-title":"Claspin, a novel protein required for the activation of Chk1 during a DNA replication checkpoint response in Xenopus egg extracts","volume":"6","author":"Kumagai","year":"2000","journal-title":"Mol. Cell"},{"issue":"19","key":"10.1016\/j.biopha.2022.113797_bib46","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1111\/febs.13387","article-title":"DNA damage control: regulation and functions of checkpoint kinase 1","volume":"282","author":"Smits","year":"2015","journal-title":"FEBS J."},{"issue":"2","key":"10.1016\/j.biopha.2022.113797_bib47","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1093\/nar\/gkr697","article-title":"Safeguarding genome integrity: the checkpoint kinases ATR, CHK1 and WEE1 restrain CDK activity during normal DNA replication","volume":"40","author":"S\u00f8rensen","year":"2012","journal-title":"Nucleic Acids Res."},{"issue":"21","key":"10.1016\/j.biopha.2022.113797_bib48","doi-asserted-by":"crossref","first-page":"7488","DOI":"10.1128\/MCB.23.21.7488-7497.2003","article-title":"Chk1 kinase negatively regulates mitotic function of Cdc25A phosphatase through 14-3-3 binding","volume":"23","author":"Chen","year":"2003","journal-title":"Mol. Cell. Biol."},{"issue":"2","key":"10.1016\/j.biopha.2022.113797_bib49","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1158\/1078-0432.CCR-09-1029","article-title":"New insights into checkpoint kinase 1 in the DNA damage response signaling network","volume":"16","author":"Dai","year":"2010","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.biopha.2022.113797_bib50","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1091\/mbc.12.3.551","article-title":"Positive regulation of Wee1 by Chk1 and 14-3-3 proteins","volume":"12","author":"Lee","year":"2001","journal-title":"Mol. Biol. Cell"},{"issue":"8","key":"10.1016\/j.biopha.2022.113797_bib51","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/nrm2450","article-title":"ATR: an essential regulator of genome integrity","volume":"9","author":"Cimprich","year":"2008","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"3","key":"10.1016\/j.biopha.2022.113797_bib52","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1042\/BJ20102162","article-title":"ATR signalling: more than meeting at the fork","volume":"436","author":"Nam","year":"2011","journal-title":"Biochem. J."},{"issue":"3","key":"10.1016\/j.biopha.2022.113797_bib53","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1535-6108(03)00048-5","article-title":"Chk1 regulates the S phase checkpoint by coupling the physiological turnover and ionizing radiation-induced accelerated proteolysis of Cdc25A","volume":"3","author":"S\u00f8rensen","year":"2003","journal-title":"Cancer Cell"},{"issue":"7","key":"10.1016\/j.biopha.2022.113797_bib54","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.dnarep.2007.02.015","article-title":"The ATR pathway: fine-tuning the fork","volume":"6","author":"Paulsen","year":"2007","journal-title":"DNA Repair"},{"issue":"5","key":"10.1016\/j.biopha.2022.113797_bib55","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1158\/0008-5472.CAN-11-2904","article-title":"ATR\u2013ATRIP kinase complex triggers activation of the Fanconi anemia DNA repair pathway","volume":"72","author":"Shigechi","year":"2012","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.biopha.2022.113797_bib56","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/sj.onc.1209828","article-title":"ATR-dependent checkpoint modulates XPA nuclear import in response to UV irradiation","volume":"26","author":"Wu","year":"2007","journal-title":"Oncogene"},{"issue":"23","key":"10.1016\/j.biopha.2022.113797_bib57","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1101\/gad.851000","article-title":"Functional interactions between BRCA1 and the checkpoint kinase ATR during genotoxic stress","volume":"14","author":"Tibbetts","year":"2000","journal-title":"Genes Dev."},{"issue":"2","key":"10.1016\/j.biopha.2022.113797_bib58","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/ncb1212","article-title":"The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair","volume":"7","author":"S\u00f8rensen","year":"2005","journal-title":"Nat. Cell Biol."},{"issue":"3","key":"10.1016\/j.biopha.2022.113797_bib59","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/bjc.2011.243","article-title":"Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines","volume":"105","author":"Peasland","year":"2011","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2022.113797_bib60","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1158\/1535-7163.MCT-08-0662","article-title":"Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells","volume":"8","author":"Parsels","year":"2009","journal-title":"Mol. Cancer Ther."},{"issue":"2","key":"10.1016\/j.biopha.2022.113797_bib61","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.molcel.2016.12.007","article-title":"Coupling of homologous recombination and the checkpoint by ATR","volume":"65","author":"Buisson","year":"2017","journal-title":"Mol. Cell"},{"issue":"2","key":"10.1016\/j.biopha.2022.113797_bib62","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.molmed.2010.10.009","article-title":"Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics","volume":"17","author":"Ma","year":"2011","journal-title":"Trends Mol. Med."},{"issue":"24","key":"10.1016\/j.biopha.2022.113797_bib63","doi-asserted-by":"crossref","first-page":"4321","DOI":"10.4161\/cc.10.24.18661","article-title":"Selective radiosensitization of p53 mutant pancreatic cancer cells by combined inhibition of Chk1 and PARP1","volume":"10","author":"Vance","year":"2011","journal-title":"Cell Cycle"},{"issue":"2","key":"10.1016\/j.biopha.2022.113797_bib64","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1124\/mi.11.2.11","article-title":"CHK1 inhibitors in combination chemotherapy: thinking beyond the cell cycle","volume":"11","author":"Dent","year":"2011","journal-title":"Mol. Interv."},{"issue":"5","key":"10.1016\/j.biopha.2022.113797_bib65","first-page":"791","article-title":"Enhancement of cisplatin-induced cytotoxicity by 7-hydroxystaurosporine (UCN-01), a new G2-checkpoint inhibitor","volume":"2","author":"Bunch","year":"1996","journal-title":"Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res."},{"issue":"1","key":"10.1016\/j.biopha.2022.113797_bib66","doi-asserted-by":"crossref","first-page":"104","DOI":"10.4161\/cc.6.1.3699","article-title":"Pharmacological abrogation of S-phase checkpoint enhances the anti-tumor activity of gemcitabine in vivo","volume":"6","author":"Matthews","year":"2007","journal-title":"Cell Cycle"},{"issue":"1","key":"10.1016\/j.biopha.2022.113797_bib67","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1158\/1535-7163.MCT-06-0371","article-title":"Cell cycle phenotype-based optimization of G2-abrogating peptides yields CBP501 with a unique mechanism of action at the G2 checkpoint","volume":"6","author":"Sha","year":"2007","journal-title":"Mol. Cancer Ther."},{"issue":"8","key":"10.1016\/j.biopha.2022.113797_bib68","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1002\/ijc.28521","article-title":"The natural anticancer compound rocaglamide selectively inhibits the G1-S-phase transition in cancer cells through the ATM\/ATR-mediated Chk1\/2 cell cycle checkpoints","volume":"134","author":"Neumann","year":"2014","journal-title":"Int. J. Cancer"},{"issue":"6","key":"10.1016\/j.biopha.2022.113797_bib69","doi-asserted-by":"crossref","first-page":"631","DOI":"10.2174\/187152012800617678","article-title":"The role of Cdc25A in the regulation of cell proliferation and apoptosis","volume":"12","author":"Shen","year":"2012","journal-title":"Anti-Cancer Agents Med. Chem."},{"issue":"11","key":"10.1016\/j.biopha.2022.113797_bib70","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1080\/15384047.2015.1078021","article-title":"Harmine suppresses homologous recombination repair and inhibits proliferation of hepatoma cells","volume":"16","author":"Zhang","year":"2015","journal-title":"Cancer Biol. Ther."},{"issue":"17","key":"10.1016\/j.biopha.2022.113797_bib71","first-page":"4375","article-title":"Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine","volume":"59","author":"Sarkaria","year":"1999","journal-title":"Cancer Res."},{"issue":"17","key":"10.1016\/j.biopha.2022.113797_bib72","doi-asserted-by":"crossref","first-page":"5678","DOI":"10.1093\/nar\/gkp593","article-title":"Inhibition of ATR protein kinase activity by schisandrin B in DNA damage response","volume":"37","author":"Nishida","year":"2009","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.biopha.2022.113797_bib73","doi-asserted-by":"crossref","unstructured":"George, V.C. and H. Rupasinghe, Apple flavonoids suppress carcinogen-induced DNA damage in normal human bronchial epithelial cells. Oxidative Medicine and Cellular Longevity, 2017. 2017.","DOI":"10.1155\/2017\/1767198"},{"issue":"2","key":"10.1016\/j.biopha.2022.113797_bib74","doi-asserted-by":"crossref","first-page":"613","DOI":"10.3892\/or.2012.2170","article-title":"Triptolide induced DNA damage in A375. S2 human malignant melanoma cells is mediated via reduction of DNA repair genes","volume":"29","author":"Chueh","year":"2013","journal-title":"Oncol. Rep."},{"issue":"02","key":"10.1016\/j.biopha.2022.113797_bib75","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1142\/S0192415X1550024X","article-title":"Kaempferol induces DNA damage and inhibits DNA repair associated protein expressions in human promyelocytic Leukemia HL-60 cells","volume":"43","author":"Wu","year":"2015","journal-title":"Am. J. Chin. Med."},{"issue":"2","key":"10.1016\/j.biopha.2022.113797_bib76","doi-asserted-by":"crossref","first-page":"4989","DOI":"10.4238\/2015.May.12.2","article-title":"Mangiferin induces cell cycle arrest at G2\/M phase through ATR-Chk1 pathway in HL-60 leukemia cells","volume":"14","author":"Peng","year":"2015","journal-title":"Genet Mol. Res"},{"issue":"1","key":"10.1016\/j.biopha.2022.113797_bib77","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3390\/biom11010079","article-title":"Mangiferin as new potential anti-cancer agent and mangiferin-integrated polymer systems\u2014a novel research direction","volume":"11","author":"Morozkina","year":"2021","journal-title":"Biomolecules"},{"issue":"7","key":"10.1016\/j.biopha.2022.113797_bib78","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1158\/1535-7163.MCT-11-0921","article-title":"Inhibition of ATR-dependent signaling by protoapigenone and its derivative sensitizes cancer cells to interstrand cross-link\u2013generating agents in vitro and in vivo","volume":"11","author":"Wang","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.biopha.2022.113797_bib79","doi-asserted-by":"crossref","first-page":"2543504","DOI":"10.1155\/2020\/2543504","article-title":"Curcumin-induced DNA demethylation in human gastric cancer cells is mediated by the DNA-damage response pathway","volume":"2020","author":"Tong","year":"2020","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.biopha.2022.113797_bib80","article-title":"Turmeric and its major compound curcumin on health: bioactive effects and safety profiles for food, pharmaceutical, biotechnological and medicinal applications","volume":"11","author":"Sharifi-Rad","year":"2020","journal-title":"Biotechnol. Med. Appl. Front. Pharmacol."},{"issue":"11","key":"10.1016\/j.biopha.2022.113797_bib81","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1093\/carcin\/bgt240","article-title":"Curcumin suppresses multiple DNA damage response pathways and has potency as a sensitizer to PARP inhibitor","volume":"34","author":"Ogiwara","year":"2013","journal-title":"Carcinogenesis"},{"issue":"11","key":"10.1016\/j.biopha.2022.113797_bib82","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1093\/carcin\/bgi165","article-title":"Resveratrol causes Cdc2-tyr15 phosphorylation via ATM\/ATR\u2013Chk1\/2\u2013Cdc25C pathway as a central mechanism for S phase arrest in human ovarian carcinoma Ovcar-3 cells","volume":"26","author":"Tyagi","year":"2005","journal-title":"Carcinogenesis"},{"issue":"3","key":"10.1016\/j.biopha.2022.113797_bib83","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/carcin\/bgm283","article-title":"Resveratrol modulates DNA double-strand break repair pathways in an ATM\/ATR\u2013p53- and \u2013Nbs1-dependent manner","volume":"29","author":"Gatz","year":"2008","journal-title":"Carcinogenesis"},{"issue":"5","key":"10.1016\/j.biopha.2022.113797_bib84","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.3892\/or.2015.3871","article-title":"Resveratrol analogue (E)-8-acetoxy-2-[2-(3, 4-diacetoxyphenyl) ethenyl]-quinazoline induces G2\/M cell cycle arrest through the activation of ATM\/ATR in human cervical carcinoma HeLa cells","volume":"33","author":"Kim","year":"2015","journal-title":"Oncol. Rep."},{"issue":"7","key":"10.1016\/j.biopha.2022.113797_bib85","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1002\/ijc.30764","article-title":"RAD51 as a potential surrogate marker for DNA repair capacity in solid malignancies","volume":"141","author":"Gachechiladze","year":"2017","journal-title":"Int. J. Cancer"},{"issue":"14","key":"10.1016\/j.biopha.2022.113797_bib86","doi-asserted-by":"crossref","first-page":"3438","DOI":"10.3390\/cancers13143438","article-title":"Exploiting DNA damage repair in precision cancer therapy: BRCA1 as a prime therapeutic target","volume":"13","author":"Raimundo","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.biopha.2022.113797_bib87","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/CEJ.0b013e328353edcb","article-title":"Resveratrol induces downregulation of DNA repair genes in MCF-7 human breast cancer cells","volume":"22","author":"Leon-Galicia","year":"2013","journal-title":"Eur. J. Cancer Prev."},{"issue":"7","key":"10.1016\/j.biopha.2022.113797_bib88","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1158\/1535-7163.MCT-11-0921","article-title":"Inhibition of ATR-dependent signaling by protoapigenone and its derivative sensitizes cancer cells to interstrand cross-link\u2013generating agents in vitro and in vivoinhibition of ATR and FANCD2 activation by natural products","volume":"11","author":"Wang","year":"2012","journal-title":"Mol. Cancer Ther."},{"issue":"2","key":"10.1016\/j.biopha.2022.113797_bib89","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.18632\/oncotarget.6482","article-title":"ATR-Chk1 signaling inhibition as a therapeutic strategy to enhance cisplatin chemosensitivity in urothelial bladder cancer","volume":"7","author":"Li","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2022.113797_bib90","doi-asserted-by":"crossref","first-page":"2172740","DOI":"10.1155\/2020\/2172740","article-title":"A comprehensive review on schisandrin B and its biological properties","volume":"2020","author":"Nasser","year":"2020","journal-title":"Oxid. Med. Cell. Longev."},{"issue":"2","key":"10.1016\/j.biopha.2022.113797_bib91","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.bbrc.2005.07.097","article-title":"Schisandrin B\u2014A novel inhibitor of P-glycoprotein","volume":"335","author":"Qiangrong","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.biopha.2022.113797_bib92","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.3390\/cancers3011351","article-title":"Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects","volume":"3","author":"Florea","year":"2011","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2022.113797_bib93","doi-asserted-by":"crossref","DOI":"10.1186\/2162-3619-4-5","article-title":"The effect of caffeine on cisplatin-induced apoptosis of lung cancer cells","volume":"4","author":"Wang","year":"2015","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.biopha.2022.113797_bib94","unstructured":"Demarcq, C., et al., The role of cell cycle progression in cisplatin-induced apoptosis in Chinese hamster ovary cells."},{"issue":"3B","key":"10.1016\/j.biopha.2022.113797_bib95","first-page":"2275","article-title":"Inhibition of cisplatin-induced ATR activity and enhanced sensitivity to cisplatin","volume":"23","author":"Yazlovitskaya","year":"2003","journal-title":"Anticancer Res."},{"issue":"3","key":"10.1016\/j.biopha.2022.113797_bib96","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.molonc.2014.10.013","article-title":"Untangling the ATR-CHEK1 network for prognostication, prediction and therapeutic target validation in breast cancer","volume":"9","author":"Abdel-Fatah","year":"2015","journal-title":"Mol. Oncol."},{"issue":"2","key":"10.1016\/j.biopha.2022.113797_bib97","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.molcel.2016.03.006","article-title":"A genome-wide CRISPR screen identifies CDC25A as a determinant of sensitivity to ATR inhibitors","volume":"62","author":"Ruiz","year":"2016","journal-title":"Mol. Cell"},{"issue":"2","key":"10.1016\/j.biopha.2022.113797_bib98","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s11060-015-2050-4","article-title":"Expression and prognostic value of the WEE1 kinase in gliomas","volume":"127","author":"Music","year":"2016","journal-title":"J. Neuro-Oncol."},{"issue":"4","key":"10.1016\/j.biopha.2022.113797_bib99","doi-asserted-by":"crossref","first-page":"795","DOI":"10.3390\/cancers13040795","article-title":"Clinical candidates targeting the ATR\u2013CHK1\u2013WEE1 axis in cancer","volume":"13","author":"Gorecki","year":"2021","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.biopha.2022.113797_bib100","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1158\/1535-7163.MCT-10-0928","article-title":"Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening","volume":"10","author":"Guzi","year":"2011","journal-title":"Mol. Cancer Ther."},{"issue":"6","key":"10.1016\/j.biopha.2022.113797_bib101","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1517\/17460441.2013.788496","article-title":"Structure-based design, discovery and development of checkpoint kinase inhibitors as potential anticancer therapies","volume":"8","author":"Matthews","year":"2013","journal-title":"Expert Opin. Drug Discov."},{"issue":"7","key":"10.1016\/j.biopha.2022.113797_bib102","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/nchembio.573","article-title":"Selective killing of ATM-or p53-deficient cancer cells through inhibition of ATR","volume":"7","author":"Reaper","year":"2011","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.biopha.2022.113797_bib103","doi-asserted-by":"crossref","unstructured":"O'Carrigan, B., et al., Phase I trial of a first-in-class ATR inhibitor VX-970 as monotherapy (mono) or in combination (combo) with carboplatin (CP) incorporating pharmacodynamics (PD) studies. 2016, American Society of Clinical Oncology.","DOI":"10.1200\/JCO.2016.34.15_suppl.2504"},{"key":"10.1016\/j.biopha.2022.113797_bib104","doi-asserted-by":"crossref","unstructured":"Plummer, E.R., et al., Phase I trial of first-in-class ATR inhibitor VX-970 in combination with gemcitabine (Gem) in advanced solid tumors (NCT02157792). 2016, American Society of Clinical Oncology.","DOI":"10.1200\/JCO.2016.34.15_suppl.2513"},{"key":"10.1016\/j.biopha.2022.113797_bib105","doi-asserted-by":"crossref","unstructured":"Shapiro, G., et al., Abstract CT012: phase 1 trial of first-in-class ATR inhibitor VX-970 in combination with cisplatin (Cis) in patients (pts) with advanced solid tumors (NCT02157792). 2016, AACR.","DOI":"10.1158\/1538-7445.AM2016-CT012"},{"key":"10.1016\/j.biopha.2022.113797_bib106","unstructured":"Dillon, M., et al. PATRIOT: A phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours. in ASCO. 2016: ASCO."},{"issue":"3","key":"10.1016\/j.biopha.2022.113797_bib107","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s00280-014-2380-5","article-title":"Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors","volume":"73","author":"Sausville","year":"2014","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"4","key":"10.1016\/j.biopha.2022.113797_bib108","article-title":"Trial watch: targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapy","volume":"2","author":"Manic","year":"2015","journal-title":"Mol. Cell. Oncol."},{"issue":"9","key":"10.1016\/j.biopha.2022.113797_bib109","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1200\/JCO.2014.57.5027","article-title":"Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors","volume":"33","author":"Daud","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.biopha.2022.113797_bib110","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1097\/CAD.0000000000000278","article-title":"Phase I study of LY2603618, a CHK1 inhibitor, in combination with gemcitabine in Japanese patients with solid tumors","volume":"26","author":"Doi","year":"2015","journal-title":"Anti-Cancer Drugs"},{"issue":"5","key":"10.1016\/j.biopha.2022.113797_bib111","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1159\/000448621","article-title":"Phase I study of CHK1 inhibitor LY2603618 in combination with gemcitabine in patients with solid tumors","volume":"91","author":"Calvo","year":"2016","journal-title":"Oncology"},{"issue":"5","key":"10.1016\/j.biopha.2022.113797_bib112","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s10637-016-0368-1","article-title":"Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer","volume":"34","author":"Scagliotti","year":"2016","journal-title":"Investig. N. Drugs"},{"issue":"10","key":"10.1016\/j.biopha.2022.113797_bib113","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.3390\/biomedicines9101476","article-title":"Antitumoral activities of curcumin and recent advances to improve its oral bioavailability","volume":"9","author":"Nocito","year":"2021","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.biopha.2022.113797_bib114","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3390\/biom11010079","article-title":"Mangiferin as new potential anti-cancer agent and mangiferin-integrated polymer systems-a novel research direction","volume":"11","author":"Morozkina","year":"2021","journal-title":"Biomolecules"},{"issue":"3","key":"10.1016\/j.biopha.2022.113797_bib115","article-title":"Resveratrol-loaded nanomedicines for cancer applications","volume":"4","author":"Annaji","year":"2021","journal-title":"Cancer Rep."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222011866?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222011866?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T11:12:46Z","timestamp":1781781166000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332222011866"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":115,"alternative-id":["S0753332222011866"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2022.113797","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Natural products targeting the ATR-CHK1 signaling pathway in cancer therapy","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2022.113797","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"113797"}}